Dr Din-Wei Ye talks about his new collaborations with various groups across Europe, including the OECI, and his hopes to develop a treatment studies program. In addition to the prevalence of specific types of cancer in China compared to the frequency in Europe and the rest of the world.
WIN 2011, 6-8 July, 2011, Paris
Shanghai Cancer Centre collaboration with Europe
Dr Din-Wei Ye – Fudan University Shanghai Cancer Centre, China
Our centre, Shanghai Cancer Centre, Fudan University, is the leading cancer centre in China which will have its eighty years anniversary this November. We have a long history and we take care of all the various malignancies in mainland China and we try to be the international cancer centre so we have a lot of collaborations with European colleagues, like colleagues from the Institute Gustave Roussy in France. Also we established a lot of clinical trial studies with colleagues in Europe and studies for basic research, translational research, and also clinical studies. Also we tried to tell the difference, how the protocols for cancer cure work in European citizens, patients, and also for Asian patients, which is very important to design the studies and treatment for different people. We just established the collaboration with the Italian cancer centres like IEO, the Institute of European Oncology, in Milan, and also the INT in Milan, which are very interesting collaborations and also I’m sure it will be a very productive collaboration in the future.
What are the most prevalent types of cancer in China?
Actually, for the Shanghai case, I guess for males it’s lung cancer. Most commonly we take care of lung cancer, oesophagus cancer and colon cancer, liver and even the prostate cancer. Prostate cancer has also dramatically increased during the last decade. For females it’s breast cancer would be the most common malignant tumours and also others – colon cancer, liver cancer in females, we also take care of that. Probably the instances of the malignancies are different between European countries and the Chinese patients but we try to tell the difference between the population incidence, why this happens, that difference, and also try to tell the difference even for some specific malignant tumours, the response for the same compounds or same protocols can get a difference, which is very important to establish very efficacy studies and treatments.
What do you hope to gain from your collaboration with the OECI?
We try to collaborate to apply for the grant, either from Europe and also for China and try to do the same protocol studies, which is helpful for both us. Also we try to design, establish some programme for training, use common sense ideas for the young, junior faculty and fellowship training which is also helpful for junior colleagues on both sides. The third one is for the treatment studies which is also like the clinical trials and also for the joint stamina junior conferences which also is helpful for both of us and which will be helpful.